Key Points
- Director Bob Gower purchased 400,000 Ensysce Biosciences shares at an average price of $0.49, investing $196,000 and increasing his ownership by 77.41% to 916,740 shares.
- Ensysce reported quarterly EPS of negative $0.20, in line with estimates, while revenue of $1.16 million fell short of the $1.20 million consensus forecast. The company continues to post significant losses.
- ENSC shares opened at $0.39, with a market capitalization of about $5.92 million; analysts maintain an overall “Sell” rating, while institutional and hedge-fund ownership stands at 5.63%.
Ensysce Biosciences, Inc. (NASDAQ:ENSC - Get Free Report) Director Bob Gower acquired 400,000 shares of the stock in a transaction on Friday, August 7th. The stock was bought at an average cost of $0.49 per share, with a total value of $196,000.00. Following the completion of the transaction, the director owned 916,740 shares in the company, valued at $449,202.60. This trade represents a 77.41% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Ensysce Biosciences Price Performance
Shares of ENSC stock opened at $0.39 on Wednesday. The company has a market capitalization of $5.92 million, a P/E ratio of -0.14 and a beta of 0.84. The company's 50-day simple moving average is $0.31 and its two-hundred day simple moving average is $0.40. Ensysce Biosciences, Inc. has a one year low of $0.23 and a one year high of $2.75.
Ensysce Biosciences (NASDAQ:ENSC - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.20). Ensysce Biosciences had a negative net margin of 280.53% and a negative return on equity of 2,550.30%. The firm had revenue of $1.16 million during the quarter, compared to the consensus estimate of $1.20 million. On average, research analysts expect that Ensysce Biosciences, Inc. will post -1.27 EPS for the current fiscal year.
Hedge Funds Weigh In On Ensysce Biosciences
A number of large investors have recently made changes to their positions in the business. Citadel Advisors LLC purchased a new stake in shares of Ensysce Biosciences during the 3rd quarter valued at $34,000. Virtu Financial LLC acquired a new stake in shares of Ensysce Biosciences in the 3rd quarter worth $34,000. DRW Securities LLC grew its stake in Ensysce Biosciences by 42.4% during the 4th quarter. DRW Securities LLC now owns 98,481 shares of the company's stock worth $91,000 after buying an additional 29,336 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its stake in Ensysce Biosciences by 100.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company's stock worth $138,000 after buying an additional 75,000 shares during the last quarter. 5.63% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of analysts recently weighed in on the stock. Wall Street Zen raised shares of Ensysce Biosciences to a "hold" rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Ensysce Biosciences in a research report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of "Sell".
Check Out Our Latest Report on Ensysce Biosciences
Ensysce Biosciences Company Profile
(
Get Free Report)
Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.
The company's lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
